MA51337A - Inhibiteurs spiro exo-aza de l'interaction ménine-mll - Google Patents

Inhibiteurs spiro exo-aza de l'interaction ménine-mll

Info

Publication number
MA51337A
MA51337A MA051337A MA51337A MA51337A MA 51337 A MA51337 A MA 51337A MA 051337 A MA051337 A MA 051337A MA 51337 A MA51337 A MA 51337A MA 51337 A MA51337 A MA 51337A
Authority
MA
Morocco
Prior art keywords
menin
exo
spiro
mll interaction
aza
Prior art date
Application number
MA051337A
Other languages
English (en)
Inventor
Patrick René Angibaud
Wei Cai
Xuedong Dai
James Patrick Edwards
Liqiang Fu
Linglong Kong
Daniel Jason Krosky
Yingtao Liu
Geb Herkert Barbara Morschhäuser
Vineet Pande
Aaron Nathaniel Patrick
Virginie Sophie Poncelet
Olivier Alexis Georges Querolle
Zhao-Kui Wan
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MA51337A publication Critical patent/MA51337A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA051337A 2017-12-20 2018-12-19 Inhibiteurs spiro exo-aza de l'interaction ménine-mll MA51337A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2017117536 2017-12-20
CN2018091521 2018-06-15

Publications (1)

Publication Number Publication Date
MA51337A true MA51337A (fr) 2020-10-28

Family

ID=66993097

Family Applications (1)

Application Number Title Priority Date Filing Date
MA051337A MA51337A (fr) 2017-12-20 2018-12-19 Inhibiteurs spiro exo-aza de l'interaction ménine-mll

Country Status (12)

Country Link
US (1) US20230039917A1 (fr)
EP (1) EP3728260A4 (fr)
JP (1) JP7307729B2 (fr)
KR (1) KR20200101389A (fr)
CN (1) CN111601807B (fr)
AU (1) AU2018389145B2 (fr)
BR (1) BR112020012461A2 (fr)
CA (1) CA3083624A1 (fr)
IL (1) IL275457A (fr)
MA (1) MA51337A (fr)
MX (1) MX2020006594A (fr)
WO (1) WO2019120209A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017214367A1 (fr) 2016-06-10 2017-12-14 Vitae Pharmaceuticals, Inc. Inhibiteurs de l'interaction ménine-mll
CN110950818B (zh) * 2019-12-18 2021-12-28 浙江海翔药业股份有限公司 顺式-2,6-二甲基吗啉的纯化方法
TW202525813A (zh) 2019-12-19 2025-07-01 比利時商健生藥品公司 經取代之直鏈螺環接衍生物
EP4132932A4 (fr) 2020-04-07 2024-04-17 Syndax Pharmaceuticals, Inc. Combinaisons d'inhibiteurs de ménine et d'inhibiteurs de cyp3a4 et procédés d'utilisation associés
CN114478568A (zh) * 2020-10-27 2022-05-13 苏州优理生物医药科技有限公司 一种噻吩并嘧啶类化合物、包含其药物组合物及其应用
EP4294798A1 (fr) * 2021-02-19 2023-12-27 Kalvista Pharmaceuticals Limited Inhibiteurs du facteur xiia
US20240417405A1 (en) 2021-05-08 2024-12-19 Janssen Pharmaceutica Nv Substituted Spiro Derivatives
CA3215379A1 (fr) 2021-05-08 2022-11-17 Olivier Alexis Georges Querolle Derives spiro substitues
IL308476A (en) 2021-05-14 2024-01-01 Syndax Pharmaceuticals Inc Inhibitors of the menin-mil interaction
CN120529900A (zh) 2022-11-24 2025-08-22 奥莱松基因组股份有限公司 用于治疗癌症的LSD1抑制剂和Menin抑制剂的组合

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102984941B (zh) 2009-09-04 2016-08-17 密执安大学评议会 用于治疗白血病的组合物和方法
EP2736901A1 (fr) 2011-07-28 2014-06-04 Cellzome Limited Analogues d'hétérocyclyl-pyrimidine en tant qu'inhibiteurs de jak
WO2014164543A1 (fr) * 2013-03-13 2014-10-09 The Regents Of The University Of Michigan Compositions comprenant des composés thiénopyrimidine et thiénopyridine et procédés d'utilisation associés
USRE49687E1 (en) 2014-09-09 2023-10-10 The Regents Of The University Of Michigan Thienopyrimidine and thienopyridine compounds and methods of use thereof
MA40957A (fr) 2014-10-09 2017-09-19 Biomarin Pharm Inc Inhibiteurs de biosynthèse d'héparane sulfate pour traiter des maladies
TWI703150B (zh) 2015-06-04 2020-09-01 美商庫拉腫瘤技術股份有限公司 用於抑制ｍｅｎｉｎ及ｍｌｌ蛋白之交互作用的方法及組合物
HK1246593A1 (zh) 2015-06-04 2018-09-14 Kura Oncology, Inc. 用於抑制menin蛋白与mll蛋白的相互作用的方法及组合物
AU2016378579A1 (en) * 2015-12-22 2018-06-14 Vitae Pharmaceuticals, Inc. Inhibitors of the menin-MLL interaction
PH12018501955B1 (en) 2016-03-16 2024-01-24 Kura Oncology Inc Bridged bicyclic inhibitors of menin-mll and methods of use
PL3429591T3 (pl) 2016-03-16 2023-07-17 Kura Oncology, Inc. Podstawione pochodne tieno[2,3-d]pirymidyny jako inhibitory meniny-mll i metody ich zastosowania
JP6991585B2 (ja) 2016-05-02 2022-01-12 ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン メニン阻害剤としてのピペリジン
WO2017207387A1 (fr) 2016-05-31 2017-12-07 Bayer Pharma Aktiengesellschaft Dérivés d'azétidine spiro condensés en tant qu'inhibiteurs de l'interaction ménine-mml1
WO2017214367A1 (fr) * 2016-06-10 2017-12-14 Vitae Pharmaceuticals, Inc. Inhibiteurs de l'interaction ménine-mll
WO2018024602A1 (fr) 2016-08-04 2018-02-08 Bayer Aktiengesellschaft 2,7-diazaspiro [4,4] nonanes
CA3033239A1 (fr) * 2016-09-14 2018-03-22 Janssen Pharmaceutica Nv Inhibiteurs spiro bicycliques de l'interaction menine-mll
CA3033020A1 (fr) 2016-09-14 2018-03-22 Janssen Pharmaceutica Nv Inhibiteurs bicycliques fusionnes de l'interaction menine-mll
AU2017326006B2 (en) 2016-09-16 2021-10-28 Vitae Pharmaceuticals, LLC. Inhibitors of the menin-MLL interaction
WO2018109088A1 (fr) 2016-12-15 2018-06-21 Janssen Pharmaceutica Nv Inhibiteurs d'azépane de l'interaction ménine-mll
US11396517B1 (en) * 2017-12-20 2022-07-26 Janssen Pharmaceutica Nv Exo-aza spiro inhibitors of menin-MLL interaction

Also Published As

Publication number Publication date
IL275457A (en) 2020-08-31
RU2020123548A (ru) 2022-01-20
EP3728260A4 (fr) 2021-08-11
CA3083624A1 (fr) 2019-06-27
JP7307729B2 (ja) 2023-07-12
CN111601807A (zh) 2020-08-28
AU2018389145B2 (en) 2023-02-02
RU2020123548A3 (fr) 2022-02-17
EP3728260A1 (fr) 2020-10-28
CN111601807B (zh) 2023-03-31
MX2020006594A (es) 2020-09-09
US20230039917A1 (en) 2023-02-09
AU2018389145A1 (en) 2020-05-21
KR20200101389A (ko) 2020-08-27
JP2021506882A (ja) 2021-02-22
WO2019120209A1 (fr) 2019-06-27
BR112020012461A2 (pt) 2020-11-24

Similar Documents

Publication Publication Date Title
MA51337A (fr) Inhibiteurs spiro exo-aza de l'interaction ménine-mll
EP3353328A4 (fr) Modulateurs de l'expression de kras
IL263586B (en) Inhibitors of the menin-mll interaction
HUE060078T2 (hu) CDK7 gátlására alkalmas vegyületek
MA46228A (fr) Inhibiteurs bicycliques fusionnés de l'interaction ménine-mll
DK3512850T3 (da) Inhibitorer af menin-mll-interaktionen
MA46180A (fr) Analogues de l'amyline
EP3526328A4 (fr) Polythérapie pour l'inhibition de c3
EP3906029A4 (fr) Inhibiteurs de l'interaction ménine-mll
PT3548033T (pt) Compostos e respectivos métodos de utilização
EP3353156A4 (fr) Inhibiteurs de l'autopalmitoylation du facteur de transcription tead
PT3368534T (pt) Ditosilato de valbenazina e polimorfos do mesmo
EP3732239A4 (fr) Composition de polyéthylène
EP3509581A4 (fr) Formulations de (r
PT3645518T (pt) Síntese de omecamtiv mecarbil
EP3443094A4 (fr) Procédés de réduction de l'expression de c9orf72
EP3415146A4 (fr) Inhibiteur de l'activation des inflammasomes
IL272851A (en) Methods of using dipivefrin
PT3457851T (pt) Derivados de sobetiroma
EP3632898A4 (fr) Antagoniste d'ep4
MA49006A (fr) Inhibiteurs d'ip6k
EP3449001A4 (fr) Inhibition de l'arnmi mir-22 par apt-110
EP3484854A4 (fr) Inhibiteurs de l'apoptose
EP3347334A4 (fr) Déshydrohalogénation d'hydrochlorofluorocarbones
EP3415524A4 (fr) INHIBITEUR D'EXPRESSION DE L'a-SYNUCLÉINE